These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27494648)

  • 1. BRAF and MEK inhibitors in pediatric glioma: new therapeutic strategies, new toxicities.
    Rizzo D; Ruggiero A; Amato M; Maurizi P; Riccardi R
    Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1397-1405. PubMed ID: 27494648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unbiased Proteomic and Phosphoproteomic Analysis Identifies Response Signatures and Novel Susceptibilities After Combined MEK and mTOR Inhibition in BRAF
    Maxwell MJ; Arnold A; Sweeney H; Chen L; Lih TM; Schnaubelt M; Eberhart CG; Rubens JA; Zhang H; Clark DJ; Raabe EH
    Mol Cell Proteomics; 2021; 20():100123. PubMed ID: 34298159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF and MEK inhibition in melanoma.
    Dossett LA; Kudchadkar RR; Zager JS
    Expert Opin Drug Saf; 2015 Apr; 14(4):559-70. PubMed ID: 25648338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings.
    Broman KK; Dossett LA; Sun J; Eroglu Z; Zager JS
    Expert Opin Drug Saf; 2019 May; 18(5):381-392. PubMed ID: 30977681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
    Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
    Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care.
    Simeone E; Grimaldi AM; Festino L; Vanella V; Palla M; Ascierto PA
    BioDrugs; 2017 Feb; 31(1):51-61. PubMed ID: 28058658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
    Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
    Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF inhibitors in cancer therapy.
    Hertzman Johansson C; Egyhazi Brage S
    Pharmacol Ther; 2014 May; 142(2):176-82. PubMed ID: 24325952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series.
    Butt SU; Mejias A; Morelli C; Torga G; Happe M; Patrikidou A; Arkenau HT
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):437-441. PubMed ID: 33537843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model.
    Grossauer S; Koeck K; Murphy NE; Meyers ID; Daynac M; Truffaux N; Truong AY; Nicolaides TP; McMahon M; Berger MS; Phillips JJ; James CD; Petritsch CK
    Oncotarget; 2016 Nov; 7(46):75839-75853. PubMed ID: 27713119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials.
    Fujimura T; Hidaka T; Kambayashi Y; Aiba S
    Expert Opin Investig Drugs; 2019 Feb; 28(2):143-148. PubMed ID: 30556435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MEK inhibitors in oncology: a patent review (2015-Present).
    Mahapatra DK; Asati V; Bharti SK
    Expert Opin Ther Pat; 2017 Aug; 27(8):887-906. PubMed ID: 28594589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF inhibitors in BRAF-V600 mutated primary neuroepithelial brain tumors.
    Preusser M; Bienkowski M; Birner P
    Expert Opin Investig Drugs; 2016; 25(1):7-14. PubMed ID: 26536389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy.
    Yao TW; Zhang J; Prados M; Weiss WA; James CD; Nicolaides T
    Oncotarget; 2015 Sep; 6(26):21993-2005. PubMed ID: 26023796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials.
    Mai R; Zhou S; Zhong W; Rong S; Cong Z; Li Y; Xie Q; Chen H; Li X; Liu S; Cheng Y; Huang Y; Zhou Y; Zhang G
    Oncotarget; 2015 Sep; 6(29):28502-12. PubMed ID: 26143635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Therapy for Melanoma.
    Wong DJ; Ribas A
    Cancer Treat Res; 2016; 167():251-62. PubMed ID: 26601866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Melanoma].
    Uhara H
    Gan To Kagaku Ryoho; 2016 Apr; 43(4):404-7. PubMed ID: 27220785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.
    Gowrishankar K; Snoyman S; Pupo GM; Becker TM; Kefford RF; Rizos H
    J Invest Dermatol; 2012 Jul; 132(7):1850-9. PubMed ID: 22437314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy of melanoma using kinase inhibitors.
    Heppt MV; Tietze JK; Graf SA; Berking C
    Curr Opin Oncol; 2015 Mar; 27(2):134-40. PubMed ID: 25602684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.